Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Aurora kinases a and b are up-regulated by myc and are essential for maintenance of the malignant state

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • den Hollander, J.
  • Rimpi, S.
  • Doherty, J. R.
  • Rudelius, M.
  • Buck, A.
  • Hoellein, A.
  • Kremer, M.
  • Graf, N.
  • Scheerer, M.
  • Hall, M. A.
  • Goga, A.
  • von Bubnoff, N.
  • Duyster, J.
  • Peschel, C.
  • Cleveland, John
  • Nilsson, J. A.
  • Keller, U.

publication date

  • September 2010

journal

  • Blood  Journal

abstract

  • Myc oncoproteins promote continuous cell growth, in part by controlling the transcription of key cell cycle regulators. Here, we report that c-Myc regulates the expression of Aurora A and B kinases (Aurka and Aurkb), and that Aurka and Aurkb transcripts and protein levels are highly elevated in Myc-driven B-cell lymphomas in both mice and humans. The induction of Aurka by Myc is transcriptional and is directly mediated via E-boxes, whereas Aurkb is regulated indirectly. Blocking Aurka/b kinase activity with a selective Aurora kinase inhibitor triggers transient mitotic arrest, polyploidization, and apoptosis of Myc-induced lymphomas. These phenotypes are selectively bypassed by a kinase inhibitor-resistant Aurkb mutant, demonstrating that Aurkb is the primary therapeutic target in the context of Myc. Importantly, apoptosis provoked by Aurk inhibition was p53 independent, suggesting that Aurka/Aurkb inhibitors will show efficacy in treating primary or relapsed malignancies having Myc involvement and/or loss of p53 function.

subject areas

  • Animals
  • Apoptosis
  • Aurora Kinase A
  • Aurora Kinase B
  • Aurora Kinases
  • B-Lymphocytes
  • BALB 3T3 Cells
  • Biomarkers, Tumor
  • Blotting, Western
  • Cell Proliferation
  • Cell Transformation, Neoplastic
  • Cells, Cultured
  • Chromatin Immunoprecipitation
  • Electrophoretic Mobility Shift Assay
  • Gene Expression Profiling
  • Gene Expression Regulation, Enzymologic
  • Humans
  • Immunoenzyme Techniques
  • Luciferases
  • Lymphoma, B-Cell
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Oligonucleotide Array Sequence Analysis
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-myc
  • RNA, Messenger
  • RNA, Small Interfering
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transfection
scroll to property group menus

Identity

PubMed Central ID

  • PMC2938839

International Standard Serial Number (ISSN)

  • 0006-4971

Digital Object Identifier (DOI)

  • 10.1182/blood-2009-11-251074

PubMed ID

  • 20519624
scroll to property group menus

Additional Document Info

start page

  • 1498

end page

  • 1505

volume

  • 116

issue

  • 9

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support